Skip to main content
. Author manuscript; available in PMC: 2023 Dec 11.
Published in final edited form as: Cell. 2022 Nov 18;185(25):4826–4840.e17. doi: 10.1016/j.cell.2022.10.023

Figure 5: DH1017.IgM protects mice more efficiently than DH1017.IgG against viremia upon lethal ZIKV challenge.

Figure 5:

A. Serum viral load in ZIKV infected 5-week-old Ifnar1−/− mice treated with DH1017.IgM at 103 pmol/dose (n=7) or 52 pmol/dose (n=5), or non-ZIKV reactive mAb DH1036.IgM (103 pmol/dose, n=4). Line at mean. Dotted line at limit of detection. B. Survival curves for each IgM intervention group. C. Human IgM serum concentrations in mice treated with 103 pmol/dose of DH1017.IgM or DH1036.IgM measured up to 10 days post-infection. D. Serum viral load in mice receiving of DH1017.IgG at 103 pmol/dose (n=8) or 515 pmol/dose (n=4). Additional 4 mice treated with 103 pmol/dose DH1017.IgM are shown. Line at mean. Dotted line at limit of detection.